Enterome To Present At The 6th Annual Trout Group Hamptons CEO Roundtable Conference On August 18th
PARIS and CAMBRIDGE, Massachusetts, August 11, 2016 /PRNewswire/ --
ENTEROME Bioscience SA, a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, is pleased to announce that its CEO Pierre Belichard will present an overview of the company at the 6th Annual Trout Group Hamptons CEO Roundtable Conference. The conference will take place on August 18th, 2016 at the Topping Rose House in Bridgehampton, NY.
About Enterome:
Enterome is pioneering the development of novel pharmaceuticals and diagnostics to support personalized therapies in microbiome-related diseases such as Inflammatory Bowel Disease (IBD), cancer and metabolic diseases.
Enterome is also leading the development of new industry standards in gut microbiome quantitative and functional analysis. This technology leadership allows Enterome to open up the new field of therapeutic target discovery in the microbiome in order to address significant unmet medical needs.
Enterome has established partnerships with leading pharmaceutical companies and academic research institutes, including Johnson & Johnson Innovation/Janssen Biotech, Takeda and Abbvie in inflammatory bowel diseases; and the Mayo Clinic and Geisinger hospitals in metabolic disorders.
The Company was established in 2012 in Paris, France to develop the discoveries made by the INRA metagenomic platform. The Company has raised a total of €32 million from leading venture capital investors (Seventure Partners, Lundbeckfond Ventures & Omnes Capital) and strategic investors (Nestlé Health Science, Shire & INRA transfer).
Additional information about Enterome is available through its website: http://www.enterome.com
Contact
Pierre Belichard, CEO
+33 1 75 77 27 87
David Dible / Mark Swallow / Marine Perrier
Citigate Dewe Rogerson
+44 207 638 9571
enterome@citigatedr.co.uk
SOURCE Enterome Bioscience SA
ENTEROME Bioscience SA, a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, is pleased to announce that its CEO Pierre Belichard will present an overview of the company at the 6th Annual Trout Group Hamptons CEO Roundtable Conference. The conference will take place on August 18th, 2016 at the Topping Rose House in Bridgehampton, NY.
About Enterome:
Enterome is pioneering the development of novel pharmaceuticals and diagnostics to support personalized therapies in microbiome-related diseases such as Inflammatory Bowel Disease (IBD), cancer and metabolic diseases.
Enterome is also leading the development of new industry standards in gut microbiome quantitative and functional analysis. This technology leadership allows Enterome to open up the new field of therapeutic target discovery in the microbiome in order to address significant unmet medical needs.
Enterome has established partnerships with leading pharmaceutical companies and academic research institutes, including Johnson & Johnson Innovation/Janssen Biotech, Takeda and Abbvie in inflammatory bowel diseases; and the Mayo Clinic and Geisinger hospitals in metabolic disorders.
The Company was established in 2012 in Paris, France to develop the discoveries made by the INRA metagenomic platform. The Company has raised a total of €32 million from leading venture capital investors (Seventure Partners, Lundbeckfond Ventures & Omnes Capital) and strategic investors (Nestlé Health Science, Shire & INRA transfer).
Additional information about Enterome is available through its website: http://www.enterome.com
Contact
Pierre Belichard, CEO
+33 1 75 77 27 87
David Dible / Mark Swallow / Marine Perrier
Citigate Dewe Rogerson
+44 207 638 9571
enterome@citigatedr.co.uk
SOURCE Enterome Bioscience SA